The Team

Prior to Mission Street, Artem was Head of UK Acquisitions and a member of the founding team of GreenOak Real Estate (now BGO), a major international real estate investment and asset management firm (at the time c. £10 Bn under management). He also previously worked for Morgan Stanley in their UK Real Estate team.

Artem’s track record spans development, asset management, real estate private equity and finance. This has included property acquisitions and corporate M&A, leading end-to-end delivery of complex development and asset management projects across the UK, and structuring debt and equity financing (both as the operating partner and capital partner).

Artem graduated with an MA (First Class Honours) in Land Economy at the University of Cambridge and sits on the Investment and Development Committee for the Institute of Cancer Research.

Archie  has 15 years’ experience in funding, development and leasing of commercial and residential property. He joined Mission Street in December 2019 from CBRE where he was a Director in the London Mixed-Use Development team.

His primary responsibility has been acquisitions, where Mission Street have successfully acquired a 1.5 million sq ft development pipeline across 5 projects in key locations, all of which were purchased off-market.

During the course of his career, Archie has successfully acquired, sold, funded and leased a broad range of high-profile projects for Lab, Office, Residential, Student, Hotel and Co-living development schemes.

Since his first building for the University of Bedfordshire in 2007, Colin has built up a significant track record in development for Research and Innovation buildings.

He joined Mission Street after 10 years at the Howard Group, a leading Cambridge property company, where he specialised in master-planning, design and delivery – this included leading the development of Unity Campus, Cambridge (a new 260k sf Research and Innovation campus)

Gabe joined from Palm Capital where he was previously Head of Asset Management, focussing on Office and Logistic assets. At Palm, Gabriel oversaw multiple ground up developments and office refurbishments totalling in excess of 1.7 million sq ft. Prior to Palm, Gabriel was a Principal at BGO for 8 years focussing on Asset Management in the UK and across Europe.

Gabriel has extensive experience across multiple asset classes and geographies, having lived and worked in the US, Italy, France and the UK. He speaks fluent French and Italian.

Simona has a variety of commercial real estate experience having joined from PATRIZIA, previously Rockspring PPIM. Within PATRIZIA, Simona has worked in various roles including fund management and transactions.

Simona assisted in managing two balanced UK pension funds with a total GAV of £900m. She has extensive experience in acquisitions and disposals having worked across multiple European geographies and across both traditional and alternative real estate sectors.

With over 30 years’ experience, Stewart has worked across the whole development life-cycle, from early stage feasibility, master planning and town planning, as well as detailed design, procurement, and delivery stages.

Stewart has held a number of senior positions on high profile mixed-use schemes. Whilst at M3, he led the team on the 800K sqft residential led Masterplan for the regeneration of Royal Mail’s Mount Pleasant site in Farringdon – he was subsequently the Property Director for HB Reavis which successfully obtained planning consent on the 1.2M sqft redevelopment of Elizabeth House in Waterloo.

Before joining Mission Street earlier in 2023, he was Development Director for Cube Real Estate, the developer responsible for the delivery of the 500ksq ft mixed masterplan that will accommodate the new European HQ for Unilever, as part of the wider regeneration of Kingston Town Centre.

Anton has extensive experience working across commercial and mixed-use residential schemes across London and the South-East of England.

Anton has 10 years development and construction experience which has included roles at Multiplex, Quintain and most recently at Avanton where he led on the delivery of large scale mixed-use development projects.

Sara has held a number of Operations positions over the course of her 20 year career. She provides a broad range of support services for the team as well as working on marketing, presentation and event materials and coordination.

Sara holds a CFA UK – IMC Certificate and speaks Italian and English.

Peter brings over 25 years of strategic, scientific, and operational experience within the pharmaceutical industry. Peter is a Partner at Epidarex Capital, where, alongside his team, he has created 25 new life science companies in the UK and the US.

Peter was site head at the Novartis Research Facility in UK, managing a team of 500 scientists, clinicians, and support functions. He was also unit head for Novartis in Cambridge (MA) during a lab and office redesign.

Throughout his career, Peter has built an expansive network of UK and Boston science companies from early-stage through to large pharma.

Combined with his ongoing work on the Executive Committee for the BioIndustry Association and various non-executive Director positions, Peter has gained a valuable insight into the occupier trends and requirements of the Life Sciences sector.

Peter graduated in Biochemistry and Microbiology at the University of Leeds and holds a Ph.D. in Biochemistry and Molecular Biology.

Jonathan brings over 25 years of Venture investment experience across the Life Science industry. Jonathan is a Founder and Partner at Rosetta Capital, a leading international secondary venture firm focused life sciences.

Rosetta’s investments include Catalyst Biosciences, Forward Pharma, Glycomimetrics, Novimmune, Paratek, Polyphor and Zealand Pharmaceuticals.

Rosetta’s notable exists include Ambit Biosciences (acquired by Daiichi Sankyo for $410m, Cytochroma (acquired by Opko for $290m), Enobia Pharmaceuticals (acquired by Alexion for $1.08bn) and GeminX Pharmaceuticals (acquired by Cephalon for $525m).

Jonathan started his investment career at Rothschild Asset Management before co-founding BioScience Managers in 2001. He has held several Board roles and is actively engaged in numerous portfolio companies as well as being an Advisor at the Oxford Science Enterprises since July 2020.

Jonathan holds a Ph.D. in Cancer Research from the University of Cambridge and a BA in Biology from the University of Oxford.

Tim brings over 11 years of investment experience in the Biotech and is a partner at Monograph Capital.

In 2018 Tim was a founding member of MiroBio, an Oxford University spin-out focused on treating a range of autoimmune and inflammatory disorders. Having initially raised $34m from top life science investors, the company expanded and was acquired by Gilead in September 2022 for $405m.

Having undertaken he MA in Natural Sciences at Cambridge University, Tim undertook his DPhil in Pharmacology at Oxford University. He has since held positions at The Boston Consulting Group (as consultant), Syncona Partners LLP (as Partner) where he was a founding team member of Autolus and Gyroscope, Third Rock Ventures Boston (as Principle) where he was on the founding team of Casma Therapeutics and Oxford Sciences Innovation (as Entrepreneur in Residence).

Tim continues to work at Ascend Gene & Cell Therapies, AviadoBio and OUTbio, London

Nick has played a leading role in growing the Bristol and South-West innovation ecosystem.

As Engine Shed’s founding director, he was responsible for the vision and business plan behind the University of Bristol and Bristol city council collaboration. He also built the award-winning SETsquared Bristol start-up incubator, actively supporting the strategic development and growth of 170 companies in the biotech, fintech and wider tech sectors. Prior to this, he was co-founder of the video communications business Motion Media Technology which was later IPO’d with a peak market cap of £270m.